Research Profile
Dr. Gordon's work is based on translational research of thoracic cancers including statistical analysis of microarray-based gene expression data, design and optimization of novel bioassays to diagnose and predict clinical outcome in cancer, elucidation of tumor molecular markers using multiple data acquisition platforms, linking gene discovery with mechanistic studies to improve the design of current treatment regimens in cancer, and preclinical investigation/validation of novel treatment approaches in the management of thoracic cancers.
Back to the top
Projects
1) Designing and validating diagnostic and prognostic tests for lung cancer and mesothelioma.
2) Exploring mechanisms to overcome drug resistance in mesothelioma by examining and targeting relevant apoptotic and survival pathways.
3) Determining the effect of mesothelioma-related candidate oncogenes (identified by microarray analysis) in normal mesothelial cells or low-grade mesothelioma cell lines in culture and in an animal model.
4) Determining the frequency and abundance of simian virus 40 (SV40) in human tumor specimens and the role (if any) of this virus in the etiology and pathobiology of multiple cancers including mesothelioma.
Back to the top
Funding
Current
 |
Type: Research Grant
Role: Principal Investigator
Period: 2003-2006
Agency: Cancer Research and Prevention Foundation
Title: “Early Detection, Diagnosis, and Prognosis of Lung Cancer Using Gene Ratios”
|
 |
Type: R03 (CA105249)
Role: Principal Investigator
Period: 2003-2006
Agency: National Cancer Institute
Title: “Diagnosis and Prognosis of Lung Cancer Using Gene Ratios”
|
|
Type: R21/R33 (CA100315)
Role: Co-Investigator
Period: 2004-2008
Agency: National Cancer Institute
Title: “Prognostic Markers in Mesothelioma”
|
 |
Type: Research Grant
Role: Principal Investigator
Period: 2005-2007
Agency: International Mesothelioma Program
Title: “Preclinical Examination of Novel Targets for Therapy in
Mesothelioma”
|
Completed
Back to the top
Publications
Original Articles Reviews, Chapters, and Editorials Patents
For the latest articles by Dr. Gavin Gordon, please visit 
and enter Gordon GJ in the query field.
Original Articles
1. Fang B, Eisensmith RC, Wang H, Kay MA, Cross RE, Landen CN, Gordon GJ, Bellinger DA, Read MS, Hu PC, Brinkhous KM, Woo SLC.Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Human Gene Therapy. 1995;6: 1039-44.
2. Fang B, Wang H, Gordon GJ, Bellinger DA, Read MS, Brinkhous KM, Woo SLC, Eisensmith RC. Lack of persistence of E1-recombinent adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs. Gene Therapy. 1996;3: 217-22.
3.Gordon GJ, Grisham JW, and Coleman WB. Liver regeneration in rats with retrorsine-induced hepatocellular injury proceeds through a novel cellular response. American Journal of Pathology. 2000;156: 607-619.
4.Gordon GJ, Grisham JW, Coleman WB.Induction of cytochrome P450 enzymes in the livers of rats treated with the pyrrolizidine alkaloid retrorsine. Experimental and Molecular Pathology. 2000;69: 17-26.
5. Gordon GJ, Grisham JW, Coleman WB. Bax-mediated apoptosis in the livers of rats after partial hepatectomy in the retrorsine model of hepatocellular injury. Hepatology. 2000;32: 312-320.
6.Gordon GJ, Coleman WB, Grisham JW. Temporal analysis of hepatocyte differentiation by small hepatocyte-like progenitor cells during liver regeneration in retrorsine-exposed rats. American Journal of Pathology. 2000;157: 771-786.
7.Gordon GJ, Butz JM, Grisham JW, Coleman WB. Isolation, short-term culture, and transplantation of small hepatocyte-like progenitor cells from retrorsine-exposed rats. Transplantation. 2002;73: 1236-1243.
8.Gordon GJ, Chen C-J, Mukhopadhyay NK, Jaklitsch MT, Richards WG, Sugarbaker DJ, Bueno R. Detection and quantification of SV40 large T-antigen DNA in mesothelioma tissues and cell lines. Oncology Reports. 2002; 9: 631-634.
9.Gordon GJ, Appasani KA, Parcells JP, Mukhopadhyay NK, Jaklitsch MT, Richards WG, Sugarbaker DJ, Bueno R. Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma. Carcinogenesis. 2002; 23: 1017-1024.
10. Hirao T, Bueno R, Chen C-J, Gordon GJ, Heilig E, Kelsey KT. Alterations of the p16INK4 locus in human malignant mesothelial tumors. Carcinogenesis. 2002; 23: 1127-1130.
11.Gordon GJ, Jensen RV, Hsiao L-L, Gullans SR, Blumenstock JE, Ramaswami S, Richards WG, Sugarbaker DJ, Bueno R. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Research. 2002;62: 4963-4967.
12.Gordon GJ, Hsiao L-L, Jensen RV, Gullans SR, Blumenstock JE, Richards WG, Sugarbaker DJ, Bueno R. Using gene expression ratios to predict outcome among patients with mesothelioma. Journal of the National Cancer Institute. 2003;95: 598-605.
13.Gordon GJ, Richards WG, Sugarbaker DJ, Jaklitsch MT, Bueno R. A prognostic test for adenocarcinoma of the lung from gene expression profiling data. Cancer Epidemiology, Biomarkers, and Prevention. 2003;12: 905-910.
14. Bueno R, Loughlin KR, Powell MH, Gordon GJ. Adiagnostic test for prostate cancer from gene expression profiling data. Journal of Urology. 2004;171:903-906.
15. Mukhopadhyay NK, Gilchrist D, Gordon GJ, Chen C-J, Bueno R, Lu ML, Salgia R, Sugarbaker DJ, Jaklitsch MT. Integrin dependent protein tyrosine phosphorylation is a key regulatory event in collagen IV mediated adhesion and proliferation of human lung tumor cell line, calu-1. Annals of Thoracic Surgery. 2004;78: 450-457.
16.Mukhopadhyay NK, Gordon GJ, Chen CJ, Bueno R, Sugarbaker DJ, Jaklitsch MT. Activation of focal adhesion kinase in human lung cancer cells involves multiple and potentially parallel signaling events. J Cell Mol Med. 2005;9:387-97.
17.Gordon GJ, Rockwell GN, Jensen RV, Rheinwald JG, Glickman JN, Aronson JP, Pottorf BJ, Nitz MD, Richards WG, Sugarbaker DJ, Bueno R. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol. 2005 ;166:1827-40.
18. Gordon GJ, Rockwell GN, Godfrey PA, Jensen RV, Glickman JN, Yeap BY, Richards WG, Sugarbaker DJ, Bueno R. Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin Cancer Res. 2005;11 :4406-14.
19.Mukhopadhyay NK, Gordon GJ, Doerre G, Liu B, Bueno R, Sugarbaker DJ, Jaklitsch MT. Histone deacetylation is directly involved in desilencing the expression of the catalytic subunit of telomerase in normal lung fibroblasts . Journal of Cellular and Molecular Medicine. 2005;9:662-669.
20.Jagadeeswaran R, Ma PC, Seiwert CY, Jagadeeswaran S, Zumba O, Nallasura V, Ahmed S, Filiberti R, Paganuzzi M, Puntoni R, Kratzke RA, Gordon GJ, Sugarbaker DJ, Bueno R, Janamanchi V, Bindokas VP, Kindler GL, Salgia R. Functional analysis of c-Met/HGF pathway in malignant pleural mesothelioma. Cancer Research. 2005;66:352-61.
21. Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, Ahmed S, Filiberti R, Paganuzzi M, Puntoni R, Kratzke RA, Gordon GJ, Sugarbaker DJ, Bueno R, Janamanchi V, Bindokas VP, Kindler HL, Salgia R. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 2006 Jan 1;66(1):352-61.
22. Gordon GJ, Deters LA, Nitz MD, Lieberman BC, Yeap BY, Bueno R. Differential diagnosis of solitary lung nodules with gene expression ratios. J Thorac Cardiovasc Surg. 2006 Sep;132(3):621-7.
23. Gordon G, Mani M, Mukhopadhyay L, Dong L, Yeap B, Sugarbaker D, Bueno R. Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma. J Pathol. 2007 Mar;211(4):439-46.
24. Gordon G, Mani M, Mukhopadhyay L, Dong L, Edenfield H, Glickman J, Yeap B, Sugarbaker D, Bueno R. Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma. J Pathol. 2007 Mar;211(4):447-54.
25. Silletti JP, Gordon GJ, Bueno R, Jaklitsch M, Loughlin KR. Prostate biopsy: past, present, and future. Urology. 2007 Mar;69(3):413-6.
Back to the top
Back to Publications
Reviews, Chapters, and Editorials
1. Bueno R, Gordon GJ. Genetics of malignant pleural mesothelioma: molecular markers and biologic targets. In: Thoracic Surgery Clinics: Mesothelioma. Sugarbaker DJ, Chang MY editors. Thoracic Surgery Clinics: Mesothelioma. Philadelphia: Elsevier.; 2004. p. 461-468.
2. Gordon GJ. Transcriptional profiling of mesothelioma using microarrays. Lung Cancer. 2005 ;49S1:S99-S103. .
3.Gordon GJ editor. Bioinformatics in Cancer and Cancer Therapy. Totowa, New Jersey: Humana Press. In Press.
4.Gordon GJ Pathobiological and clinical implications of global gene expression patterns in lung cancer. In: Gordon GJ editor. Bioinformatics in Cancer and Cancer Therapy. Totowa, New Jersey: Humana Press; In Press.
Back to the top
Back to Publications
Patents
1. Gordon GJ, Jensen RV, Gullans SR, Bueno R. (2003) Diagnostic and prognostic tests for cancer. U.S. Patent #US2003219760.
Back to the top
Back to Publications
Contact Information
Gavin Gordon, Ph.D.
Brigham and Women's Hospital
221 Longwood Avenue
BLI Bldg. Room 137
Boston, MA 02115
Tel: 617.732.6526
Fax: 617.582.6085
Email: ggordon@partners.org
Back to the top
Send Feedback to: 
